Regeneron pays $40 million upfront to Telix for initial work on four solid tumor radiopharma programs, using Regeneron's antibodies and Telix's manufacturing platform12.
Option to expand to four more programs with additional upfront payments1.
Potential $2.1 billion in milestones and royalties per program if Telix opts out of 50/50 profit-sharing; equal split of commercialization costs and profits otherwise1.
Includes diagnostics collaboration, with Telix leading commercialization and Regeneron receiving a profit share1.
Announced April 13, 2026; aims to combine with Regeneron's Libtayo for cancers like lung cancer12.
Sources:
1. https://www.fiercebiotech.com/biotech/regeneron-rides-radiopharma-21b-biobucks-pact-australias-telix
2. https://www.americanpharmaceuticalreview.com/1315-News/625114-Telix-and-Regeneron-Sign-Radiopharma-Collaboration-Worth-Up-to-2-1B-Including-40M/